drugset / Trial / NCT01421121

Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants

NCT01421121

Phase 2 Completed 540 enrolled Sinovac Biotech Co., Ltd
RandomizedParallel-groupDouble-blindPrevention

Summary

A randomized, placebo-controlled, double-blind clinical trial is to evaluate the safety and immunogenicity of a new inactivated EV71 vaccine developed by Sinovac Biotech CO., LTD.

Timeline

Start
2011-06
Primary completion
2011-09
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EV71 vaccine Vaccine 100 iu
Subject EV71 vaccine Vaccine 200 iu
Subject EV71 vaccine Vaccine 400 iu